We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 135 for:    (complementary OR alternative) medicine AND (woman OR women OR female) | cancer

Integrative Oncology Outcomes Study in Breast Cancer (IO-OS-BC)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01366248
First Posted: June 6, 2011
Last Update Posted: July 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Fred Hutchinson Cancer Research Center
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
Lotte & John Hecht Memorial Foundation
Information provided by (Responsible Party):
Bastyr University
May 31, 2011
June 6, 2011
July 28, 2017
August 2010
December 2017   (Final data collection date for primary outcome measure)
  • Aim 1: Describe treatments received by breast cancer patients receiving physician level practitioner IO care and the cost of IO care. [ Time Frame: Baseline, 6, 12, 24, 36, 48, and 60 months post study enrollment. ]
    Will also describe how long after diagnosis women with breast cancer seek IO care and differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care. This patient cohort will consist of all female patients with breast cancer seeking IO clinic care. Our analyses will describe how long after diagnosis women with breast cancer seek IO care and describe differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care.
  • Aim 2: Compare health-related quality of life (HRQOL) experienced by a group of breast cancer patients receiving IO care with HRQOL of a group of matched comparison women. [ Time Frame: 6-60 months post-enrollment ]
    Comparison will be between breast cancer patients living in the same geographic area with similar prognostic characteristics (age, stage of cancer at diagnosis, estrogen receptor/ progesterone receptor (ER/PR) status, race, ethnicity, and marital status) at the time of their initial diagnosis with breast cancer who did not receive IO care. We will identify an average of three (up to four each) matched controls for each eligible IO clinic cancer patient from the Western Washington CSS database and to invite them to enroll in the outcomes study.
Changes in Health-Related Quality of Life (HRQOL) and differences in Clinical Outcomes in patients who use CAM at IO clinics compared to breast cancer patients who only use conventional treatment. [ Time Frame: 6, 12, 24, 36, 48, and 60 months post study enrollment. ]
Describe HRQOL & clinical outcomes of integrated conventional & naturopathic care during treatment & 6, 12, 24, 36, 48 & 60 months post enrollment. Each case enrolled at the IO clinics will be compared to 4 found through linking with data in the Cancer Surveillance System at FHCRC. Assessed outcomes include cancer symptoms, conventional treatment side effects, IO treatment adverse effects, HRQOL during treatment, compliance with recommended conventional & IO care, use of self-prescribed CAM, HRQOL in survivorship, achievement of disease free status, disease free survival, & overall survival.
Complete list of historical versions of study NCT01366248 on ClinicalTrials.gov Archive Site
  • Aim 3: Collect pilot data on survival, comorbidities, and abnormal laboratory values. [ Time Frame: 6-60 months post-enrollment ]
    Collect pilot data on disease-free, progression free, and overall survival, as well as comorbidities and abnormal laboratory values at 6 months post-enrollment for all Cohort 1 and Cohort 2. We will collect data at 1 year post-enrollment and then yearly on disease-free, progression free, and overall survival, as well as comorbidities for as long as funding is available in a nested cohort of IO breast cancer patients (Cohort 1A) and their matched comparison group who did not receive care at any of the IO clinical sites (Cohort 2).
  • Aim 4: Describe and compare CAM treatments [ Time Frame: Baseline, 6, 12, 24, 48, and 60 months ]
    Describe and compare the frequency of use of a variety of CAM treatments used by breast cancer patients who do (Cohort 1A) and do not (Cohorts 2A and 2B) receive IO care from an IO specialist.
  • Aim 5: Compare the HRQOL of women who self-prescribe CAM with those who do not [ Time Frame: Baseline and 6, 12, 24, 36, 48 and 60 months post-enrollment ]
    To compare baseline and changes in HRQOL in breast cancer patients who self-prescribe CAM (Cohort 2B) matched with comparison women who do not use CAM (Cohort 2A).
Not Provided
Not Provided
Not Provided
 
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study

This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.

Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own.

Not Provided
Observational
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Eligible participants for the study will include patients who are receiving care for their cancer at participating Seattle area IO clinics. An average of two (up to four) matched comparison controls will be recruited from the Washington State CSS.

All breast cancer patients seeking care at the participating IO clinics who meet inclusion/exclusion criteria are eligible to participate in this study. Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.

Breast Cancer
Not Provided
  • IO Clinic Breast Cancer Patients
    Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
  • CSS Match-Control Patients
    For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
750
December 2017
December 2017   (Final data collection date for primary outcome measure)

The patients enrolled into the study will include patients who meet the following criteria:

Cohort 1: IO clinic breast cancer patients

  1. Confirmed breast cancer of primary breast cancer with ICD9 code of 174.x, 233.0 or V10.3
  2. Female
  3. ≥18 years of age
  4. Can provide signed informed consent
  5. 1st IO clinic visit ≤3 months prior to enrollment
  6. Can read and understand the questionnaires

Cohort 1A: Sub-cohort of IO clinic patients (cases) who meet the following additional criteria and for whom matched controls have been found from the CSS database.

  1. ICD9 code of 174.x or 233.0
  2. Primary ductal or lobular breast cancer diagnosis ≤2 years prior to 1st IO clinic visit
  3. Minimum of two IO clinic visits within 7 months
  4. Provided Baseline Questionnaire

Cohort 2: Matched controls from CSS database for Cohort 1A patients

  1. Confirmed breast cancer
  2. Female
  3. ≥ 18 years of age
  4. Can provide informed consent
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01366248
09E-1237-01
1R01AT005873 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Bastyr University
Bastyr University
  • Fred Hutchinson Cancer Research Center
  • National Institutes of Health (NIH)
  • National Center for Complementary and Integrative Health (NCCIH)
  • Lotte & John Hecht Memorial Foundation
Principal Investigator: Leanna J. Standish, ND, PhD, FABNO Bastyr University
Principal Investigator: M. Robyn Andersen, PhD, MPH Fred Hutchinson Cancer Research Center
Bastyr University
July 2017